Compare Neurocrine Biosciences Inc (NBIX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Synchrony Financial — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Synchrony Financial is the larger of the two by market cap, and Synchrony Financial pays a 1.84% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Synchrony Financial for 28 Days on average.
| NBIX | SYF | |
|---|---|---|
Market Cap | $14.36B | $23.99B |
Volume | 1,237,180 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $185.50 | $88.47 |
52-Week Low | $123.10 | $63.78 |
Typical Hold Time | 23 Days | 28 Days |
Enterprise Value | $14.37B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Synchrony Financial (SYF) trades at $71.93, down 0.32% today, with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 23.4% net income margin and 22.23% ROE, trading at attractive valuations (P/E 7.56x). Recent developments include partnerships with OpenAI and Vetspire to expand AI-driven commerce and veterinary financing capabilities, while Q3 2026 earnings are scheduled for October 20, 2026.
SYF presents a compelling value opportunity with strong earnings momentum and analyst consensus target of $87.58 (22% upside). However, technical weakness and increased investing outflows in 2026 create near-term headwinds. The stock offers shareholder returns through dividends and buybacks, but faces risks from consumer credit quality and competitive payment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
